Emricasan reduces portal pressure in cirrhosis despite missing endpoint

VIENNA — Emricasan missed its primary endpoint of hepatic venous pressure gradient reduction in all patients with nonalcoholic steatohepatitis-related compensated cirrhosis and severe portal hypertension but showed meaningful reductions in portal pressure among patients with high-risk disease, according to a presentation at the International Liver Congress 2019.
“Severe portal hypertension in cirrhosis is a key driver of decompensation and decompensation, in turn, is a key driver of death,” Guadalupe Garcia-Tsao, MD, from Yale University in Connecticut, said during her

Source link

WordPress database error: [Error writing file '/tmp/MYSHd8Xo' (Errcode: 28 - No space left on device)]
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND wp_posts.ID NOT IN (189582) AND ( wp_term_relationships.term_taxonomy_id IN (37) ) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') GROUP BY wp_posts.ID ORDER BY RAND() LIMIT 0, 3

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy